Answers are grounded in this paper and cite their sources.
Introduction: Non-AIDS comorbidities, metabolic, renal and bone toxicities associated to combined antiretroviral therapy (cART), namely NRTIs, led to dual therapy (NUC sparing regimens). Tenofovir Alafenamide Fumarate (TAF) demonstrated improved renal and bone safety profile over TDF even with mild to moderate renal impairment.
No takes yet. Share an insight, caveat, or question.
Abreu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: